Efforts to ease competition concerns could be having a positive impact on pharmaceutical companies’ willingness to make submissions for combination therapies to England’s health technology assessment (HTA) institute, NICE, according to a Pink Sheet analysis of NICE data.
Has Competition Reassurance Helped Counter Combination Woes In The UK?
The rate of non-submissions for combination therapies in England has been on a downward trend in the last two years.
More from Health Technology Assessment
More from Pathways & Standards
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
The FDA’s accelerated approval draft guidance has left stakeholders seeking clarification of the process for determining a surrogate marker or intermediate clinical endpoint is reasonably likely to confirm clinical benefit.